Antibodies to human MCP-1

摘要

Disclosed is a MCP-1 binding molecule which comprises: an antigen binding site with at least one immunoglobulin heavy chain variable domain (VH) which includes in sequence hypervariable regions CDR1, CDR2 and CDR3. CDR1 has the amino acid sequence His-Tyr-Trp-Met-Ser, CDR2 has the amino acid sequence Asn-Ile-Glu-Gln-Asp-Gly-Ser-Glu-Lys-Tyr-Tyr-Val-Asp-Ser-Val-Lys-Gly, and CDR3 has the amino acid sequence Asp-Leu-Glu-Gly-Leu-His-Gly-Asp-Gly-Tyr-Phe-Asp-Leu; and/or can comprise an antigen binding site with at least one immunoglobulin light chain variable domain (VL) which includes in sequence hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Gly-Val-Ser-Ser-Ala-Leu-Ala, said CDR2' having the amino acid sequence Asp-Ala-Ser-Ser-Leu-Glu-Ser, and said CDR3' having the amino acid sequence Gln-Gln-Phe-Asn-Ser-Tyr-Pro; and direct equivalents. Also disclosed are specific amino acid sequences that the MCP-1 binding molecule may have, DNA constructs that encode the molecule, methods of their production and their use as a medicament for the treatment of an MCP-1- or eotaxin-medicated disease or disorder.